• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Grand Rounds

What Are the Risks for Women Who Are FMR1 Permutation Carriers?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Women who carry a permutation in the Fragile-X gene (FMR1) are at risk for
    • Fragile X–associated primary ovarian insufficiency (FXPOI) | Affects approximately 20 to 30% carriers
    • Fragile X–associated tremor–ataxia syndrome (FXTAS): Affects approximately 6 to 15% carriers
    • More information on Fragile X premutation available in ‘Related ObG Topics’ below
  • Recent evidence suggests other health-related risks beyond these two disorders
  • Allen et al. (Genetics in Medicine, 2020) examined whether there are other medical issues among women with an FMR1 permutation

METHODS:

  • Participants identified from
    • Previous study on Fragile X | Scientific conferences | Collaborations with other research groups | Additional affected family members
    • Eligibility was based on FMR1 permutation carrier status, age, and sex
    • FXPOI diagnosis: Menopause <40 years (excluding iatrogenic causes such as oophorectomy)
    • A blood or saliva sample was collected from each participant
    • Each participant also completed a reproductive and health history questionnaire, which included
      • General demographics (e.g., age at interview, date of birth, race/ethnicity)
      • Lifestyle factors that might affect overall health (e.g., smoking, body mass index [BMI])
      • Reproductive history (e.g., menstrual history, reason for cessation of menses, pregnancy history)
      • General medical history

RESULTS:

  • 355 carrier women
  • 22 health conditions were reported by ≥10% of participants
  • The following were reported >30% of participants
    • Anxiety
    • Depression
    • Migraine and tension headaches
  • Only peripheral neuropathy was associated with repeat size
  • The number of comorbid conditions was significantly associated with body mass index (BMI) and history of smoking, but not age
  • Women with FXPOI had earlier age at onset for anxiety and osteoporosis vs those without FXPOI (p = 0.001)
  • The authors identified eight clusters of women who reported similar patterns of comorbid conditions
    • Clusters: (1) minimal health problems (2) headaches (3) sleep problems (4) mental health problems, (5) FXPOI with minimal health problems (6) FXPOI with mental health problems (7) FXPOI with complex profiles (8) FXTAS
    • Largest cluster: Minimal health problems
    • 63% fell into three categories primarily defined by the presence of only a few conditions
      • Minimal health problems | Headaches | FXPOI with minimal health problems clusters
    • A single cluster defined women with symptoms of FXTAS and no FXPOI

CONCLUSION:

  • Most women who are FMR1 permutation carriers appear to have minimal comorbid conditions
  • Authors expected other comorbid conditions to be associated with FXPOI but the converse was true
  • Women with symptoms of FXTAS appear not to overlap with women who have FXPOI symptoms

Learn More – Primary Sources:

Clustering of comorbid conditions among women who carry an FMR1 premutation

Now You Can Get ObG Clinical Research Summaries Direct to Your Phone, with ObGFirst

Try it Free  »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

Prenatal & Preconception Carrier Screening for Fragile X: Clinical and Genetic Essentials
Intellectual Disability Defined
Infertility Evaluation: Who, When and How

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site